Efficacy and safety of tenectaplase versus streptokinase in treating st-elevation myocardial infarction patients in Hong Kong: A four-year retrospective review in Queen Elizabeth Hospital

Abstract

Objective: Data were lacking in comparing tenectaplase (TNK) and streptokinase (SK) in treating Chinese ST elevation myocardial infarction (STEMI) patients. We sought to compare these 2 types of thrombolytics in our locality. Methods: We analysed 196 STEMI patients who received either TNK or SK in our hospital from 2007 to 2011. We compared the mortality and other outcomes of these 2 groups of patients. Results: In-hospital mortality has no significant difference between the TNK and the SK groups (8.9% vs 5.3%, p=0.322). Door-to-needle time was shorter in the TNK group (31±10 vs 25±7, p<0.001). Hypotension after drug administration was more common in the SK group than in the TNK group (21.1% vs. 3.0%, p<0.001). Conclusion: TNK is at least as safe as SK in treating STEMI patients, with the advantage of shorter door-to-needle time and less frequent hypotensive effect.